Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer

被引:67
作者
Seetoo, DQ
Crowe, PJ
Russell, PJ
Yang, JL [1 ]
机构
[1] Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia
[2] Prince Wales Hosp, Dept Surg, Sydney, NSW, Australia
[3] Univ New S Wales, Dept Clin Med, Sydney, NSW, Australia
关键词
colorectal cancer; plasminogen activation system; uPA; uPAR; survival;
D O I
10.1002/jso.10210
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives: Certain pathophysiological markers may be helpful in selecting further therapies for patients with resected colorectal cancer (CRC). The aim of this study was to determine whether expression of proteins of the plasminogen activation system (PAS), which are important in tumor spread and growth, can predict outcome of human CRC. Methods: Protein expression of the PAS, including urokinase-type plasminogen activator (uPA) and its receptor (uPAR), plasminogen (Plg), and plasminogen activator inhibitors-1 and -2 (PAI-1 and PAI-2), was determined in the colonic tissue samples of 56 patients with resected primary CRC by quantitative immunohistochemistry and correlated with clinicopathological parameters and patient outcome. Results: Overexpression of uPA (t-test, P < 0.001), uPAR (P < 0.001) and PAI-1 (P = 0.031) was significantly associated with liver metastatic CRC tumors. Higher uPA or uPAR expression level was significantly correlated with overall survival (OS; log-rank, P = 0.001 and P < 0.0001) and cancer-specific survival (CSS; P = 0.001 and P < 0.0001) after the first CRC resection. The predictive value of both uPA and uPAR in liver metastasis, OS and CSS was independent from other parameters (multivariate Cox regression: all P < 0.001). Conclusions: uPA and uPAR may be independent predictors of liver metastasis, patient overall survival and cancer-specific survival after resection of colorectal tumors. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:184 / 193
页数:10
相关论文
共 27 条
[1]  
Abe J, 1999, CANCER-AM CANCER SOC, V86, P2602, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2602::AID-CNCR4>3.0.CO
[2]  
2-S
[3]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[4]  
2-Z
[5]  
Baker EA, 2000, J CLIN PATHOL-MOL PA, V53, P307
[6]   Overexpression of nm23 protein assessed by color video image analysis in metastatic colorectal cancer: Correlation with reduced patient survival [J].
Berney, CR ;
Yang, JL ;
Fisher, RJ ;
Russell, PJ ;
Crowe, PJ .
WORLD JOURNAL OF SURGERY, 1998, 22 (05) :484-490
[7]   ANTIGEN LEVELS OF UROKINASE PLASMINOGEN-ACTIVATOR AND ITS RECEPTOR AT THE TUMOR-HOST INTERFACE OF COLORECTAL ADENOCARCINOMAS ARE RELATED TO TUMOR AGGRESSIVENESS [J].
BUO, L ;
MELING, GI ;
KARLSRUD, TS ;
JOHANSEN, HT ;
AASEN, AO .
HUMAN PATHOLOGY, 1995, 26 (10) :1133-1138
[8]   THE PLASMIN SYSTEM IN HUMAN COLONIC TUMORS - AN IMMUNOFLUORESCENCE STUDY [J].
BURTIN, P ;
CHAVANEL, G ;
ANDRE, J .
INTERNATIONAL JOURNAL OF CANCER, 1985, 35 (03) :307-314
[9]   The plasminogen activation system in tumour invasion and metastasis [J].
deVries, TJ ;
vanMuijen, GNP ;
Ruiter, DJ .
PATHOLOGY RESEARCH AND PRACTICE, 1996, 192 (07) :718-733
[10]  
Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO